Medications for Refractory Diffuse Large Bcell Lymphoma Not Otherwise Specified

2 results

  • monjuvi

    (Tafasitamab-cxix)
    MorphoSys US Inc.
    MONJUVI, in combination with lenalidomide, is indicated for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplant. Approval is based on overall response rate and may require further verification of clinical benefit.

  • zynlonta

    (loncastuximab tesirine)
    ADC Therapeutics America, Inc.
    ZYNLONTA is indicated for adult patients with relapsed or refractory large B-cell lymphoma following two or more systemic therapies, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and variants. Approval is based on overall response rates, with continued approval dependent on further confirmation of clinical benefit.